Long Acting Reversible Contraception After Surgical Abortion With High Rate of Continuation and Patients' Satisfaction.

Journal of Family and Reproductive Health Pub Date : 2024-06-01 DOI:10.18502/jfrh.v18i2.15931

Paola Algeri, Laura Imbruglia, Laura Colonna, Vanda Savoldi, Nunzia Mastrocola, Silvia Von Wunster

{"title":"Long Acting Reversible Contraception After Surgical Abortion With High Rate of Continuation and Patients' Satisfaction.","authors":"Paola Algeri, Laura Imbruglia, Laura Colonna, Vanda Savoldi, Nunzia Mastrocola, Silvia Von Wunster","doi":"10.18502/jfrh.v18i2.15931","DOIUrl":null,"url":null,"abstract":"Objective: In Italy the percentage of repeated abortions is about 24%. Long-acting reversible contraceptive (LARC) methods are currently considered the most effective mode worldwide and are associated with the highest rate of 12-months continuation, with a potential reported reduction of recurrent abortions. The aim of this study was evaluating LARC continuation and the patients' satisfaction at two and twelve months in use.Materials and methods: A longitudinal observational study collected women who underwent surgical abortion and placed a LARC method at the time of abortion in our hospital.Results: Totally 828 women underwent surgical abortion during the study period from which 434 choose a LARC method. After two months the rate of continuation of 52mg LNG IUD was 100% in women presenting for follow-up. Continuation rate at one year was approximately 70% for all LARC methods. More than 70% of women declared themselves satisfied or very satisfied with all LARC methods.Conclusion: Despite a high rate of patient loss at follow-up, LARC methods showed a high rate of continuation at two and twelve months, with a high degree of patients' satisfaction.","PeriodicalId":15845,"journal":{"name":"Journal of Family and Reproductive Health","volume":"18 2","pages":"90-93"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11246740/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Family and Reproductive Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/jfrh.v18i2.15931","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: In Italy the percentage of repeated abortions is about 24%. Long-acting reversible contraceptive (LARC) methods are currently considered the most effective mode worldwide and are associated with the highest rate of 12-months continuation, with a potential reported reduction of recurrent abortions. The aim of this study was evaluating LARC continuation and the patients' satisfaction at two and twelve months in use.

Materials and methods: A longitudinal observational study collected women who underwent surgical abortion and placed a LARC method at the time of abortion in our hospital.

Results: Totally 828 women underwent surgical abortion during the study period from which 434 choose a LARC method. After two months the rate of continuation of 52mg LNG IUD was 100% in women presenting for follow-up. Continuation rate at one year was approximately 70% for all LARC methods. More than 70% of women declared themselves satisfied or very satisfied with all LARC methods.

Conclusion: Despite a high rate of patient loss at follow-up, LARC methods showed a high rate of continuation at two and twelve months, with a high degree of patients' satisfaction.

查看原文本刊更多论文

手术流产后长效可逆避孕药的持续使用率和患者满意度高。

目的：在意大利，重复流产的比例约为 24%。长效可逆避孕法（LARC）目前被认为是世界上最有效的避孕方法，也是持续使用 12 个月率最高的避孕方法，据报道可能会减少重复流产。本研究旨在评估 LARC 使用两个月和十二个月后的持续率和患者满意度：一项纵向观察研究收集了在本医院接受手术流产并在流产时使用 LARC 方法的妇女：结果：在研究期间，共有 828 名妇女接受了手术流产，其中 434 人选择了 LARC 方法。两个月后，接受随访的妇女继续使用 52 毫克 LNG 宫内节育器的比例为 100%。所有 LARC 方法在一年后的继续率约为 70%。超过 70% 的妇女对所有 LARC 方法表示满意或非常满意：尽管随访时患者的流失率很高，但 LARC 方法在两个月和十二个月后的继续使用率很高，患者的满意度也很高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Family and Reproductive Health

自引率

0.00%

发文量

审稿时长

5 weeks

期刊介绍： The Journal of Family & Reproductive Health (JFRH) is the quarterly official journal of Vali–e–Asr Reproductive Health Research Center. This journal features fulllength, peerreviewed papers reporting original research, clinical case histories, review articles, as well as opinions and debates on topical issues. Papers published cover the scientific and medical aspects of reproductive physiology and pathology including genetics, endocrinology, andrology, embryology, gynecologic urology, fetomaternal medicine, oncology, infectious disease, public health, nutrition, surgery, menopause, family planning, infertility, psychiatry–psychology, demographic modeling, perinatalogy–neonatolgy ethics and social issues, and pharmacotherapy. A high scientific and editorial standard is maintained throughout the journal along with a regular rate of publication. All published articles will become the property of the JFRH. The editor and publisher accept no responsibility for the statements expressed by the authors here in. Also they do not guarantee, warrant or endorse any product or service advertised in the journal.